← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	1,222	+21	+2%	$15.1B
2	2 Charles River Laboratories CRL $14.4B	621	+10	+2%	$10.1B
3	3 DELISTED CATALENT, INC. CTLT	434	-7	-2%	$9.04B
4	4 CRISPR Therapeutics CRSP $4.86B	405	-12	-3%	$2.5B
5	5 Sarepta Therapeutics SRPT $1.78B	395	-10	-2%	$10.1B
6	6 Intellia Therapeutics NTLA $1.6B	285	-5	-2%	$2.53B
7	7 BridgeBio Pharma BBIO $12.7B	220	+24	+12%	$4.24B
8	8 Ultragenyx Pharmaceutical RARE $1.47B	220	-22	-9%	$2.52B
9	9 Vericel Corp VCEL $2.06B	213	+13	+7%	$1.73B
10	10 Legend Biotech LEGN $3.7B	200	+6	+3%	$5.78B
11	11 Krystal Biotech KRYS $9.79B	188	+5	+3%	$2.76B
12	12 PTC Therapeutics PTCT $4.98B	180	-25	-12%	$1.84B
13	13 Rocket Pharmaceuticals RCKT $243M	175	+11	+7%	$1.83B
14	14 Fate Therapeutics FATE $232M	170	-18	-10%	$203M
15	15 DELISTED bluebird bio BLUE	168	-7	-4%	$273M
16	16 uniQure QURE $1.45B	159	-18	-10%	$240M
17	17 Regenxbio RGNX $454M	159	-7	-4%	$610M
18	18 Allogene Therapeutics ALLO $449M	154	-17	-10%	$413M
19	19 DELISTED BioLife Solutions BLFS	153	-3	-2%	$602M
20	20 DELISTED 2seventy bio TSVT	146	-3	-2%	$215M
21	21 Precigen PGEN $2.64B	138	0	0%	$86M
22	22 DELISTED Arcellx ACLX	136	-2	-1%	$1.71B
23	23 Sana Biotechnology SANA $698M	136	+13	+11%	$493M
24	24 DELISTED SANGAMO THERAPEUTICS INC SGMO	134	-18	-12%	$61.3M
25	25 Caribou Biosciences CRBU $49.3M	126	+6	+5%	$338M